The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study
Open accessAbstract
SUMMARY BACKGROUND Dietary avoidance is recommended for peanut allergies. We evaluated sustained effects of peanut allergy oral immunotherapy (OIT) in the first randomized long-term study in adults and children. METHODS Peanut allergic participants (7–55 years-old) underwent a double-blind, placebo-controlled, phase 2 study. Participants randomized 2·4:1·4:1 in a 2×2 block design received placebo (oat flour) or peanut protein. Active therapy participants were built up to and maintained on 4 g peanut protein through week 104 then either discontinued peanut (peanut-0) or ingested 300 mg daily (peanut-300) for 52 weeks. Double-blind, placebo-controlled, food challenges (DBPCFCs) to 4 g peanut protein were conducted at baseline and weeks 104, 117, 130, 143 and 156. The primary endpoint was passing DBPCFCs at 104 and 117 weeks. This trial is registered at ClinicalTrials.gov (). FINDINGS Participants recruited between April 15, 2014 and March 2, 2016 were enrolled into peanut-0 (60), peanut-300 (35) and placebo (25) arms. At week 117, 35% peanut-0 and 4% placebo participants achieved success (OR [95%CI] 12·7 [1·8, 554·8]). While time to treatment failure (i.e., failing DBPCFCs to 4 g peanut over time) was significantly longer in peanut-300 vs. peanut-0, the proportion of participants passing DBPCFCs in peanut-300 declined significantly from week 104 to 156 (weeks 104 vs 156; 83% vs. 37%, OR [95%CI] 7·9 [2·4, 29·9]). The most common adverse events (AEs) were mild gastrointestinal symptoms; AEs decreased over time in all arms. In peanut-0, in which 13% passed DBPCFCs at week 156, higher baseline peanut-specific IgG4/IgE and lower Ara h 2 IgE and basophil activation responses were associated with sustained unresponsiveness. INTERPRETATION Peanut OIT can desensitize most peanut-allergic individuals to 4 g peanut protein but discontinuation, or even reduction to 300 mg daily, increases the likelihood of regaining clinical reactivity to peanut. Baseline blood tests correlate with week 117 treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boyce, J. A., Assa'ad, A., Burks, A. W., Jones, S. M., Sampson, H. A., Wood, R. A., Plaut, M., Cooper, S. F., Fenton, M. J., Arshad, S. H., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.10.008 · Cited by 2,350
Self-citationThe prevalence, severity, and distribution of childhood food allergy in the United States
Gupta, R. S., Springston, E. E., Warrier, M. R., Smith, B., Kumar, R., Pongracic, J., & Holl, J. L. (2011) · PEDIATRICS · doi:10.1542/peds.2011-0204 · Cited by 1,417
(2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.10.007 · Cited by 1,267
AR101 Oral Immunotherapy for Peanut Allergy
The PALISADE Group of Clinical Investigators (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1812856 · Cited by 765
Double-blind, placebo-controlled food challenge (DBPCFC) as an office procedure: A manual
Allan Bock, S., Sampson, H. A., Atkins, F. M., Zeiger, R. S., Lehrer, S., Sachs, M., Bush, R. K., & Metcafe, D. D. (1988) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(88)90135-2 · Cited by 714
ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice.
Bhuiyan, P. S., & Rege, N. N. (2001) · PubMed · Cited by 527
Syed, A., Garcia, M. A., Lyu, S.-C., Bucayu, R., Kohli, A., Ishida, S., Berglund, J. P., Tsai, M., Maecker, H., O’Riordan, G., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.12.1037 · Cited by 490
Self-citationChu, D. K., Wood, R. A., French, S., Fiocchi, A., Jordana, M., Waserman, S., Brożek, J. L., & Schünemann, H. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30420-9 · Cited by 448
Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy
Vickery, B. P., Scurlock, A. M., Kulis, M., Steele, P. H., Kamilaris, J., Berglund, J. P., Burk, C., Hiegel, A., Carlisle, S., Christie, L., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.11.007 · Cited by 436
Anagnostou, K., Islam, S., King, Y., Foley, L., Pasea, L., Bond, S., Palmer, C., Deighton, J., Ewan, P., & Clark, A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62301-6 · Cited by 422
Cited by
EAACI Molecular Allergology User's Guide 2.0
Dramburg, S., Hilger, C., Santos, A. F., de las Vecillas, L., Aalberse, R. C., Acevedo, N., Aglas, L., Altmann, F., Arruda, K. L., Asero, R., et al. (2023) · Pediatric Allergy and Immunology · doi:10.1111/pai.13854 · Cited by 298
Food Allergy from Infancy Through Adulthood
Sicherer, S. H., Warren, C. M., Dant, C., Gupta, R. S., & Nadeau, K. C. (2020) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.02.010 · Cited by 201
Self-citationMechanisms of Oral Immunotherapy
Barshow, S. M., Kulis, M. D., Burks, A. W., & Kim, E. H. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.13824 · Cited by 94
Bringing the Next Generation of Food Allergy Diagnostics Into the Clinic
Santos, A. F., Kulis, M. D., & Sampson, H. A. (2022) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2021.09.009 · Cited by 60
Basophil Activation Test in the Food Allergy Clinic: Its Current Use and Future Applications
Bergmann, M. M., & Santos, A. F. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2336568 · Cited by 39
Metadata
- Authors
- Chinthrajah, R. S., Purington, N., Andorf, S., Long, A., O'Laughlin, K. L., Lyu, S. C., Manohar, M., Boyd, S. D., Tibshirani, R., Maecker, H., Plaut, M., Mukai, K., Tsai, M., Desai, M., Galli, S. J., & Nadeau, K. C.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 394
- Issue
- 10207
- Pages
- 1437-1449
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2972623358
- Cited by
- 331
- References
- 36
- FWCI
- 22.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. https://app.cochat.ai/papers/10.1016/s0140-6736(19)31793-3
- The paper
- Chinthrajah, R. S., Purington, N., Andorf, S., Long, A., O'Laughlin, K. L., Lyu, S. C., Manohar, M., Boyd, S. D., Tibshirani, R., Maecker, H., Plaut, M., Mukai, K., Tsai, M., Desai, M., Galli, S. J., & Nadeau, K. C. (2019). Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. The Lancet. https://doi.org/10.1016/s0140-6736(19)31793-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
